Seattle, WA, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Lila Biologics (“Lila”), an AI/ML-driven protein therapeutics biotech company, today announced a global licensing and multi-target research collaboration with Eli Lilly and Company (“Lilly”) focused on the discovery, development, and commercialization of novel radioligand therapies (RLTs) for imaging and treatment of solid tumors. Lila also announced the launch of its two protein therapeutic platforms, driven by artificial intelligence (AI) and machine learnin ...